Drug Delivery to Primary and Metastatic Brain Tumors: Challenges and Opportunities

Surabhi Talele, Afroz S. Mohammad, Julia A. Schulz, Bjoern Bauer, Anika M.S. Hartz, Jann N. Sarkaria, William F. Elmquist

Research output: Chapter in Book/Report/Conference proceedingChapter


The effective treatment of brain tumors is a considerable challenge in part due to the presence of the blood-brain barrier (BBB) that limits drug delivery. Multiple hurdles pose challenges in identifying drugs that may be effective in treating brain tumors, including limited central nervous system (CNS) distribution of therapeutics, heterogeneous disruption of the blood-brain barrier in the regions of the tumor that lead to heterogenous drug distribution within the tumor, and genetic heterogeneity of tumor drivers. This chapter discusses the current standard of care and its limitations, as well as complex challenges in the treatment of primary and metastatic brain tumors. We review a variety of prospective delivery solutions of therapeutics to the brain and CNS for the treatment of brain tumors that will in the future lead to opening new doors for more effective treatments.

Original languageEnglish (US)
Title of host publicationAAPS Advances in the Pharmaceutical Sciences Series
Number of pages40
StatePublished - 2022

Publication series

NameAAPS Advances in the Pharmaceutical Sciences Series
ISSN (Print)2210-7371
ISSN (Electronic)2210-738X


  • Active transporters
  • Antibody drug conjugates
  • Blood-tumor barrier
  • Glioblastoma
  • Immunotherapy
  • Receptor mediated transport

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Drug Delivery to Primary and Metastatic Brain Tumors: Challenges and Opportunities'. Together they form a unique fingerprint.

Cite this